Loading organizations...
Loading organizations...
LakeShore Biopharma develops and manufactures human-used vaccines and therapeutic biologics, primarily focusing on infectious diseases and oncology. The company leverages its proprietary PIKA® immunomodulating technology platform to create next-generation preventive and therapeutic treatments. Its current offerings include a freeze-dried human rabies vaccine, with a pipeline featuring innovative candidates for rabies, COVID-19, and hepatitis B, demonstrating a broad approach to immunology.
The company, originally established as YS Biopharma in 1994 by founder Yi Zhang, emerged from the insight to safeguard human health through advanced medical solutions. Its early efforts focused on developing the first domestically refined and adjuvant-free purified rabies vaccines for human use, addressing critical public health needs. This foundational work laid the groundwork for its continued expansion and technological advancements in biopharmaceuticals.
LakeShore Biopharma's products serve patients globally, with operations spanning China, the United States, Singapore, and the Philippines, reaching those in need of protection against infectious diseases and cancer. The company’s long-term vision centers on continuously delivering new generations of vaccines and therapeutic biologics, driven by a commitment to rigorous science and a mission to enhance global health outcomes.
LakeShore Biopharma has raised $130.0M across 1 funding round.
LakeShore Biopharma has raised $130.0M in total across 1 funding round.
LakeShore Biopharma is a global biopharmaceutical company specializing in the development, manufacturing, and commercialization of vaccines and therapeutic biologics primarily for infectious diseases and cancer. Its main products include a freeze-dried human rabies vaccine and a proprietary PIKA® immunomodulating technology platform, which supports a pipeline of vaccines targeting rabies, hepatitis B, shingles, influenza, and COVID-19. The company serves healthcare providers and public health sectors by addressing critical needs in infectious disease prevention and treatment, with cumulative sales of its rabies vaccine exceeding 100 million units, demonstrating strong growth momentum[1][2][3].
Founded in 2002 in Beijing, China, LakeShore Biopharma (formerly YS Biopharma) evolved from a domestic vaccine developer into an internationally recognized innovative vaccine company. Its leadership team combines extensive local expertise and global vision, guiding the company through key milestones such as the development of the PIKA rabies vaccine, a major new drug project supported by China’s Ministry of Science and Technology. The company rebranded to LakeShore Biopharma in May 2024 to reflect its broader global ambitions and expanded operations across China, Singapore, the United States, the United Arab Emirates, and the Philippines[2][4].
LakeShore Biopharma rides the global trend of increasing demand for innovative vaccines and immunotherapies amid rising infectious disease threats and cancer prevalence. The timing is favorable due to heightened public health awareness, government support for vaccine innovation, and advances in immunomodulation technology. By advancing novel vaccines and therapeutic biologics, LakeShore influences the broader biopharma ecosystem through technology innovation and expanding access to critical vaccines worldwide[2][4].
Looking ahead, LakeShore Biopharma is positioned to expand its pipeline with next-generation vaccines and immunotherapies, leveraging its PIKA platform to address unmet medical needs in infectious diseases and oncology. Trends such as increasing global vaccination efforts, personalized immunotherapies, and emerging infectious threats will shape its growth trajectory. The company’s evolving influence is likely to grow as it strengthens its global presence and contributes to the advancement of vaccine technology and public health solutions on an international scale[2][4].
LakeShore Biopharma has raised $130.0M in total across 1 funding round.
LakeShore Biopharma's investors include OrbiMed, Dave Chenn, 3W Capital, Adjuvant Capital, AIHC Capital, Eight Roads Ventures, Epiphron Capital, F-Prime Capital, Haitong International, Hillhouse Capital, MSA Capital, Superstring Capital.
LakeShore Biopharma has raised $130.0M across 1 funding round. Most recently, it raised $130.0M Series B in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2021 | $130.0M Series B | OrbiMed, Dave Chenn | 3W Capital, Adjuvant Capital, AIHC Capital, Eight Roads Ventures, Epiphron Capital, F-Prime Capital, Haitong International, Hillhouse Capital, MSA Capital, Superstring Capital |
